FDA Grants Orphan Drug Designation to Keros’ KER-065 for Duchenne Muscular Dystrophy
Keros Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to KER-065 for the treatment of Duchenne muscular dystrophy (DMD), a…
Read More...
Read More...
